Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
magazineClose to 50% gain from Equals since April, more to come?
Equals (EQLS:AIM) 63.99p
Gain to date: 48.8%
Original entry point: Buy at 43p, 29 April 2021
Payments group Equals (EQLS:AIM) reported half year numbers that were ahead of analysts’ expectations. Group revenue increased by 23% to £16.9 million. Adjusted EBITDA (earnings before interest, tax, depreciation and amortisation), increased by 128% to £1.6 million.
Third quarter revenue to 10 September was £9.2 million, equating to a 58% increase year-on-year. A key factor behind this outperformance is Equals Solutions, a new multi-currency product aimed at larger corporates. Although the platform was only launched in June it has attracted new customers and has secured a strong pipeline of orders. In Q3, it generated £1.2 million of revenue, 13% of the group total.
The outlook is robust and will be driven by the confluence of two factors. First, the business-to-business revenue continues to grow as the group’s investment in technology in previous years is now bearing fruit. Second, the easing of travel restrictions will boost the consumer business.
Following the update, Canaccord Genuity says it now expects 2021 revenue to be 6% higher than its previous forecast and 2022 to be 5% higher. ‘Positive operational gearing implies that our earnings per share forecasts are upgraded by 8% in each year,’ it adds.
SHARES SAYS: Keep buying.
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
Issue contents
Editor's View
Feature
Great Ideas
- China exposure is a key risk for Lindsell Train Equity Fund
- Alliance Pharma's growth potential remains underappreciated
- Why this Japanese trust has gained 15% in a month
- Close to 50% gain from Equals since April, more to come?
- Want Asia exposure but worried about China? Try Vietnam
- A brighter outlook for property makes this 5% yielding trust a bargain
